3/4/2009

A study funded by the U.S. Department of Veterans Affairs showed that the combination of anti-clotting drug Plavix and stomach drugs known as proton pump inhibitors increased the risk of death or hospital readmission by 25%. A spokeswoman for Plavix maker Bristol-Myers Squibb said the company is working with the FDA to address the issue. She advised health care professionals to "re-evaluate the need for starting or continuing treatment" with the stomach medicines.

Full Story:
Bloomberg

Related Summaries